X‑linked hypophosphatemic rickets bone pain - Causes, Treatment & When to See a Doctor

What is X‑linked hypophosphatemic rickets bone pain?

X‑linked hypophosphatemic rickets (XLH) is a rare, inherited disorder of phosphate metabolism caused by mutations in the PHOSPHO1 (more precisely the PHEX) gene located on the X chromosome. The mutation leads to excess production of fibroblast growth factor‑23 (FGF‑23), a hormone that tells the kidneys to discard phosphates in the urine. Low serum phosphate impairs the body’s ability to mineralize growing bone, producing the classic signs of rickets in children and osteomalacia in adults.

Bone pain is one of the most common and often disabling symptoms of XLH. It results from weakened, poorly mineralized bone that is susceptible to micro‑fractures, deformities, and abnormal stress on joints. The pain can be chronic, worsens with activity, and may interfere with sleep, school, work, and quality of life.

Common Causes

While XLH itself is the primary driver of bone pain in affected individuals, several related or co‑existing conditions can exacerbate the discomfort. The most frequent contributors include:

• FGF‑23 excess – the hallmark biochemical abnormality that forces phosphate loss.
• Secondary hyperparathyroidism – chronic low phosphate can stimulate parathyroid hormone, further weakening bone.
• Osteomalacia – adult‑type softening of bone due to persistent phosphate deficiency.
• Rickets‑related deformities – bowed legs (genu varum), knocked knees (genu valgum), and wrist/ankle mal‑alignments place uneven stress on the skeleton.
• Micro‑fractures – tiny, often unnoticed cracks that accumulate in under‑mineralized bone.
• Enthesopathy – abnormal calcification at tendon and ligament attachment sites, common in XLH.
• Dental abnormalities – defective dentin can cause tooth pain that mimics bone pain.
• Joint arthropathy – early‑onset osteoarthritis from abnormal joint loading.
• Physical inactivity – muscles become weaker and place extra load on fragile bone.
• Medication side‑effects – long‑term use of certain phosphate binders or high‑dose vitamin D can cause gastrointestinal discomfort that may be misinterpreted as bone pain.

Associated Symptoms

Patients with XLH often experience a constellation of signs that accompany bone pain:

• Growth retardation or short stature.
• Leg deformities (bowed legs, knock‑knees).
• Dental problems – spontaneous tooth loss, large pulp chambers, enamel defects.
• Joint stiffness or swelling, especially in the hips, knees, and ankles.
• Muscle weakness, particularly proximal (hip and shoulder) muscles.
• Fatigue and reduced exercise tolerance.
• Recurrent low‑impact fractures.
• Hearing loss (rare, due to middle‑ear ossicle demineralization).
• Calcification of tendons/ligaments (enthesopathy) causing painful nodules.

When to See a Doctor

Because untreated XLH can lead to irreversible skeletal deformities and chronic pain, timely medical evaluation is essential. Seek professional care promptly if you notice any of the following:

• Persistent bone or joint pain that does not improve with rest.
• New or worsening limb deformities (bowed/kneeling legs, uneven shoulder height).
• Difficulty walking, frequent falls, or inability to keep up with peers/colleagues.
• Dental pain, spontaneous tooth loss, or visible cavities despite good oral hygiene.
• Unexplained bruising or fractures after minor trauma.
• Stunted growth or a height percentile that falls far below family expectations.
• Signs of vitamin D deficiency (muscle aches, bone tenderness) that do not resolve with over‑the‑counter supplements.

Diagnosis

Diagnosing XL­‑related bone pain involves a combination of clinical assessment, laboratory testing, and imaging.

Clinical Evaluation

• Detailed medical and family history (XLH follows an X‑linked dominant inheritance pattern; males often more severely affected).
• Physical exam focusing on stature, limb alignment, joint range of motion, and dental health.

Laboratory Tests

• Serum phosphate – typically low (<2.5 mg/dL in children, <2.7 mg/dL in adults).
• Serum calcium – usually normal.
• Alkaline phosphatase (ALP) – elevated due to increased bone turnover.
• Intact FGF‑23 level – high in XLH (helps differentiate from other phosphaturic disorders).
• 25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D – often low/normal.
• Kidney function panel to rule out renal causes of phosphate loss.

Genetic Testing

Sequencing of the PHEX gene confirms the diagnosis in >95% of classic cases. Testing is recommended for the proband and at‑risk relatives.

Imaging Studies

• Radiographs – show widening of growth plates, metaphyseal cupping, and bowing of long bones.
• Dual‑energy X‑ray absorptiometry (DEXA) – assesses bone mineral density (often low).
• Bone scintigraphy – detects areas of increased turnover or micro‑fractures.
• Dental X‑rays – evaluate for dentin defects and pulp chamber enlargement.

Treatment Options

Modern therapy aims to correct phosphate wasting, improve bone mineralization, and alleviate pain while minimizing side‑effects.

Medication

• Burosumab (Crysvita®) – a monoclonal antibody that blocks FGF‑23, restoring renal phosphate reabsorption. Large‑scale trials show significant improvements in serum phosphate, growth velocity, and pain scores (Miller et al., NEJM 2020).
• Oral phosphate salts (e.g., sodium phosphate) – traditionally combined with active vitamin D analogs; requires multiple daily doses and careful monitoring for hyperparathyroidism.
• Active vitamin D analogs (calcitriol or alfacalcidol) – promote intestinal calcium and phosphate absorption; dosage is titrated to avoid hypercalcemia.
• Analgesics – acetaminophen or NSAIDs for intermittent pain, used under physician guidance.

Physical & Occupational Therapy

• Weight‑bearing exercises (e.g., walking, low‑impact aerobics) stimulate bone formation.
• Strengthening of core and lower‑extremity muscles reduces stress on deformities.
• Stretching programs help maintain joint range of motion and prevent contractures.

Surgical Interventions

• Corrective osteotomies for severe leg bowing (usually performed after growth plates close).
• Dental restorations or extractions for teeth with poor dentin quality.
• Joint replacement in cases of early‑onset osteoarthritis.

Lifestyle & Home Measures

• Balanced diet rich in natural phosphate (lean meats, dairy, nuts) while avoiding excess processed phosphates that can aggravate renal load.
• Adequate calcium intake (1,000–1,300 mg/day) as directed by the care team.
• Regular, moderate‑intensity physical activity (30 min most days).
• Heat or cold packs to the painful area for symptomatic relief.
• Maintaining a healthy weight to lessen joint stress.

Prevention Tips

Because XLH is genetic, the condition itself cannot be prevented, but many complications—including severe bone pain—can be mitigated:

• Early diagnosis: Family screening and genetic testing enable treatment before irreversible deformities develop.
• Adherence to prescribed therapy: Missing doses of burosumab or phosphate supplements can cause rapid return of symptoms.
• Routine monitoring: Quarterly labs (phosphate, calcium, PTH, ALP) and annual imaging help adjust therapy promptly.
• Injury avoidance: Use protective gear during sports and practice safe lifting techniques.
• Dental care: Brush twice daily, floss, and see a dentist familiar with XLH every 6 months.
• Vaccinations: Stay up‑to‑date on flu and pneumococcal vaccines; infections can exacerbate metabolic imbalances.

Emergency Warning Signs

Bottom Line

X‑linked hypophosphatemic rickets is a lifelong metabolic bone disease that frequently presents with chronic bone pain. Early recognition, genetic confirmation, and targeted therapy—especially with the FGF‑23 inhibitor burosumab—have transformed outcomes, allowing many patients to lead active, pain‑controlled lives. Nonetheless, vigilance for complications, regular follow‑up, and prompt medical attention for red‑flag symptoms remain essential.

For further reading and evidence‑based guidelines, see:

• Mayo Clinic. Hypophosphatemic rickets.
• National Institutes of Health (NIH). NIH Rare Diseases Information Center.
• American Academy of Pediatrics. Clinical practice guideline for the management of rickets (2022).
• Miller, PJ et al. “Burosumab Therapy for X‑Linked Hypophosphatemia.” New England Journal of Medicine. 2020;382:2115‑2125.
• Cleveland Clinic. Hypophosphatemic Rickets.